Davutamig

达伏妥米单抗

Report date: 2024/02/02 17:55:29

Base Information

Drug NameDavutamig

Drug Alias NameREGN-5093

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionHepatocyte growth factor receptor inhibitors

TargetsHepatocyte growth factor receptor

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFranceSouth Korea

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesRegeneron Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

Other Information

ATC CodeN/A